A case of maturity-onset diabetes of the young type 4 in Korea

Geu-Meum Park; Soojung Lee; Ja Young Seo; Kyung In Lim

doi:10.6065/apem.2142188.094

Ann Pediatr Endocrinol Metab > Volume 28(2); 2023 > Article

Park, Lee, Seo, and Lim: A case of maturity-onset diabetes of the young type 4 in Korea

Case Report

Annals of Pediatric Endocrinology & Metabolism 2022;28(2): 149-154.

Published online: May 16, 2022

DOI: https://doi.org/10.6065/apem.2142188.094

A case of maturity-onset diabetes of the young type 4 in Korea

Geu-Meum Park¹

, Soojung Lee², Ja Young Seo³

, Kyung In Lim¹

¹Department of Pediatrics, Gachon University Gil Medical Center, Incheon, Korea

²Department of Pediatrics, Ajou University Hospital, Ajou University School of Medicine, Suwon, Korea

³Department of Laboratory Medicine, Gachon University Gil Medical Center, Incheon, Korea

Address for correspondence: Kyung In Lim Department of Pediatrics, Gachon University Gil Medical Center, 21 Namdong-daero 774beon-gil, Namdong-gu, Incheon 21565, Korea Email: lki830720@gilhospital.com

Received September 9, 2021 Revised November 8, 2021 Accepted November 15, 2021

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Maturity-onset diabetes of the young (MODY) is a rare, autosomal dominant disease characterized by non-ketogenic diabetes mellitus (DM). MODY type 4, caused by PDX1 mutation, is a very rare subtype of MODY, especially in Korea. We report a case of a 10-year-old, nonobese girl with a family history of type 2 DM. After diagnosis, the patient’s serum glucose level was well controlled using metformin monotherapy; however, the glycated hemoglobin level increased to 9.0% approximately 2 years after treatment. No obesity or lifestyle problems were observed, and serum fasting C-peptide level was within the normal range. Furthermore, no islet-related autoantibodies were detected. A genetic screening for MODY using a next-generation sequencing panel was performed, and a likely heterozygous pathogenic PDX1 mutation (p.Gly246ArgfsTer21) was identified. The PDX1 variant was not detected in her mother, implying that the mutation had arisen de novo in the proband. She was prescribed insulin degludec in addition to metformin therapy, which improved her hyperglycemia. This report presents a novel MODY type 4 phenotype and highlights the importance of genetic screening in patients with MODY characteristics.

Keywords: Maturity-onset diabetes of the young, PDX1, MODY type 4

Highlights

· MODY type 4 is an infrequent form of monogenic diabetes brought on by heterozygous mutations in the PDX1 gene. We report the first case of MODY type 4 phenotype in Korea and should consider using genetic analysis for precise diagnosis with MODY.

Introduction

Diabetes mellitus (DM) in children and adolescents has increased worldwide and is a heterogeneous disease, with most cases corresponding to type 1 and type 2 DM [1]. Although type 1 DM is the most common form in pediatric patients, type 2 DM and monogenic diabetes have also been detected [2].

Monogenic diabetes can include maturity-onset diabetes in youth (MODY), neonatal diabetes, and mitochondrial diabetes, resulting from mutations in genes encoding transcription factors or other proteins that regulate pancreas development or function [3]. MODY is one of the most common types of monogenic diabetes, accounting for less than 5.0% of all patients with DM [4] or 1%–6% of patients with DM [2]. Generally, MODY is characterized by an autosomal dominant inheritance that can be transmitted by either parent or occurs as a de novo mutation. It is classically characterized by a nonacute and nonketotic presentation, typically occurring before 25 years of age [5]. As patients with MODY rapidly fail treatment with oral drugs or do not present with ketosis, they can be classified as type 1 DM or type 2 DM [5].

MODY type 4 is generally caused by heterozygous mutations in the pancreas and duodenum homeobox-1 (PDX1) gene, a pancreatic homeodomain transcription factor that is critically involved in both early pancreatic development and the regulation of β-cell function [6]. MODY type 4 is a rare form that presents a few cases of PDX1 mutations [6]. Clinical presentation of MODY type 4 patients includes a variable age of onset with obese or nonobese phenotype and is managed with diet, oral antidiabetic medications, and/or insulin [4].

In Korea, MODY cases have been reported in 11 studies, with examples of the most common forms of glucokinase (GCK)-MODY, hepatocyte nuclear factor-1 homeobox A (HNF1A)-MODY, and hepatocyte nuclear factor-4 homeobox A (HNF4A)-MODY [7]. PDXI mutation-associated MODY type 4 is extremely rare in Korea; here, we describe the first case of a Korean girl who was initially diagnosed with type 2 DM.

Case report

A 10-year-old girl visited our outpatient clinic for hyperglycemia as a result of a serum glucose test performed at a local pediatric clinic due to glucosuria detected during a school checkup. At the first visit, she was nonobese, her height was 146.3 cm (50th–75th percentile for age), bodyweight 32.4 kg (25th–50th percentile for age), and body mass index 15.14 kg/m² (10th–25th percentile for age). Her mother had been diagnosed with type 2 DM at the age of 34 years and had developed gestational DM at the age of 26 years with no diabetic complications. At diagnosis of type 2 DM, her mother’s body mass index (BMI) was 20.3 kg/m² and glycated hemoglobin (HbA1c) level was 12.9%. Her mother was being effectively controlled with oral antidiabetic medication. Additionally, her 2 maternal uncles had been recently diagnosed with type 2 DM. Her father and elder sister both were nondiabetic. The patient’s pedigree is shown in Fig. 1.

The initial fasting plasma glucose (FPG), HbA1c, fasting C-peptide, and 2-hour postprandial C-peptide after meal levels were 159 mg/dL, 13.6%, 0.84 ng/mL (normal range, 0.8–4.2 ng/mL), and 24.44 ng/mL, respectively. No islet-related autoantibodies, including insulin autoantibodies, antiglutamic acid decarboxylase antibodies, or anti-islet cell antibodies, were detected in the blood. Based on these results, the patient was diagnosed with type 2 DM and received metformin monotherapy. Her serum glucose level was well managed, and her HbA1c level decreased to <7.0% after treatment. However, after 2 years of metformin monotherapy, her serum glucose level deteriorated, and her HbA1c level increased to 9.0%, although there were no changes in body weight and lifestyle, including diet. She was admitted to our hospital for hyperglycemic management and workup.

Upon admission, her height was 154 cm (10th–25th percentile for age), bodyweight 41.6 kg (10th–25th percentile for age), and body mass index 17.54 kg/m² (10th–25th percentile for age). Other physical examinations were common. FPG level was 163 mg/dL and HbA1c was 9.0%, with a fasting C-peptide level of 1.08 ng/mL and a 2-hour postprandial C-peptide level of 1.47 ng/mL. No other abnormal liver or kidney function was detected.

Based on these findings, a slight decrease in endogenous insulin secretion combined with early onset, nonobesity, antibody-negativity, and a family history of diabetes, MODY was suspected. Genetic tests were performed after obtaining written informed consent of the patient and her mother. Screening of MODY-related genes using next-generation sequencing (NGS) panel analysis detected the PDX1 variant, a heterozygous duplication of c.735dup (p.Gly246ArgfsTer21) in exon 2 of the PDX1 gene (Fig. 2), which was diagnosed as MODY type 4 and was not reported. Based on the 2015 guidelines developed by the American College of Medical Genetics and Genomics/Association for Molecular Pathology for classification of pathogenic or likely pathogenic variants, the PDX1 mutation identified in our proband was "likely pathogenic" [8]. The variant results in a glycine (Gly) to arginine (Arg) substitution at position 246, which results in a premature termination codon. Her mother's sample was also subjected to NGS, and no mutations were detected. The clinical and laboratory data of this Korean family are presented in Table 1.

Insulin therapy was added to metformin monotherapy because of the potential decrease in insulin secretion as the pancreatic function might be gradually reduced. The patient commenced treatment with metformin and insulin degludec combination therapy.

After hospital discharge, the patient was treated with metformin and insulin combination therapy. Based on follow-up examinations, HbA1c was maintained below 7%, and no comorbidities were found; therefore, this combination therapy was continued and adjusted according to changes in the serum glucose and HbA1c levels (Fig. 3).

This study was approved by the Institutional Review Board of Gil Medical Center (approval number: GCIRB2021-324). The authors have informed the patient of the use of data and clinical pictures for publication purposes.

Discussion

MODY is an autosomal dominant inherited disorder that presents early in life due to defects in the development of optimum β-cells or failure in their function. At least 14 types of MODY that are diagnosed in diabetes patients are caused by mutations in several essential genes, such as GCK, HNF1A, hepatocyte nuclear factor-1 homeobox B (HNF1B), and PDX1 [9].

Recently, MODY was suspected in a patient with a family history of diabetes in 1 parent and first-degree relatives of the affected parent, with lack of characteristics of type 1 DM, including the absence of autoantibodies, a small requirement for insulin supplementation, and lack of type 2 DM characteristics, which is distinct from obesity and acanthosis nigricans [2]. In addition, in the case of patients with diabetes in the first 6 months of life, molecular neonatal DM (NDM) screening should immediately be conducted [2]. MODY is often misdiagnosed as type 1 or type 2 DM, and it is estimated that > 80% of MODY cases are not diagnosed by molecular testing, as in the present case [10].

In the present case, progressive hyperglycemia was observed for several years due to a mutation in PDX1. Initially, the disease was misdiagnosed as type 2 DM because of her clinical features, where the lack of pancreatic islet autoantibodies was not detected, stimulated serum C-peptide level was higher than 0.6 ng/mL, and there were no other endocrine diseases. Although she had been treated with metformin since she was diagnosed with type 2 DM, the patient abruptly presented with hyperglycemia without any evidence of a trigger. There is a need for reinvestigation that aids the diagnosis of either type 1 DM or MODY. Genetic analysis revealed a mutation in PDX1, which is associated with MODY type 4.

MODY type 4 is a rare form of monogenic diabetes caused by heterozygous mutations in the PDX1 gene, which encodes the transcription factor PDX1 crucial for pancreatic and beta-cell development and function. Homozygous mutations in PDX1 result in pancreas agenesis associated with NDM [6,11]. However, heterozygous mutations in PDX1 are associated with DM in humans, suggesting that PDX1 plays a role in islet compensation for insulin resistance or glucose-stimulated insulin release, particularly in postprandial hyperglycemia [6]. Caetano et al. reported a heterozygous PDX1 variant that revealed caudal pancreatic agenesis and no main pancreatic duct of this segment on computed tomography [12].

Duplication in exon 2 of the PDX1 gene c.735dup has not been detected in Korea. The proband's mother, who had been diagnosed with type 2 DM, did not have a PDX1 gene mutation. Her father, who was nondiabetic, did not undergo a genetic analysis; thus, we assumed that our proband was affected by a de novo mutation, which is considered rare [13]. Nevertheless, recent epidemiological studies have demonstrated that such mutations in the major MODY genes, such as GCK, HNF1A, and HNF4A, could be more frequent than previously assumed [13].

Various clinical characteristics of patients diagnosed with MODY type 4 have been described in several studies (Table 2). The age at onset is distributed widely from neonatal to 26 years, with a mean age of 10 years. Most patients test negative for β-cell antibodies. HbA1c of previous patients with available data at diagnosis of MODY ranged from 7.4%–10.7%, all diabetic HbA1c level ≥6.5%. However, our proband's BMI was lower than that reported in other cases. Unfortunately, it is not possible to compare each clinical feature due to insufficient patient information. Further detailed case reports demonstrating disease progression and complications are necessary to improve the existing knowledge of MODY type 4.

Therapeutic management of MODY type 4 has not yet been established because the traditional criteria of MODY identify a low proportion of patients and are not sufficiently sensitive to be used alone in clinical practice [14]. Nevertheless, the effectiveness of oral antidiabetic medications, such as metformin and dipeptidyl peptidase 4 inhibitors, has been reported in MODY type 4 cases [14-16]. Some cases reported the use of insulin as a primary therapeutic agent [17]. Al-Kandari et al. [18] found a missense variant of c.461C > G (p. Thr154Arg) in a 16-year-old Kuwaiti proband who was receiving insulin treatment. In that case, the switch from treatment with metformin only to insulin combination treatment with metformin was successful and led to reasonable control of glycemia.

A correct genetic diagnosis impacts the treatment and identifies at-risk family members. Thus, it is essential to consider a diagnosis of MODY in appropriate individuals and to pursue genetic testing to establish a molecular diagnosis. Molecular analysis using targeted-NGS provides simultaneous analysis of the genes in a single panel at a cost comparable to Sanger sequencing [19].

The present case had some limitations. We were not able to test the patient’s father, sibling, or 2 maternal uncles for the detected gene mutation to determine whether the mutation arose de novo.

To the best of our knowledge, there have been no reports of PDX1-MODY in Korea [7]. This report describes the first such case of MODY type 4, caused by a heterozygous PDX1 mutation c.735dup (p.Gly246ArgfsTer21). This emphasizes the diversity of clinical manifestations of MODY type 4 and the importance of genetic screening and counseling in these patients. Genetic and personalized diagnosis and treatment are crucial for young patients with nonclassical forms of diabetes.

Notes

Conflicts of interest

No potential conflict of interest relevant to this article was reported.

Funding

This study received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

Author contribution

Formal analysis: SL; Project administration: KIL; Visualization: JYS; Writing - original draft: GMP; Writing - review & editing: KIL

Fig. 1.

Pedigree of diabetes mellitus in the case family. Black symbols indicate individuals with diabetes, and open symbols indicate nondiabetic individuals. The arrow indicates the proband. Two maternal uncles recently had been diagnosed with type 2 diabetes mellitus; however, her mother did not know their exact information. Genotype is indicated by N, normal sequence allele and M, mutant allele. Age at diagnosis of diabetes (A) and present age (B) are represented as A/B.

Fig. 2.

Results of Sanger sequencing of exon 2 in the PDX1 gene of the proband and her mother. (A) Binary alignment map visualization of the variant in PDX1. A partial sequence of PDX1 NM_000209.3 is shown. The position of the PDX1 exon 2 mutation c.735dup (p.Gly246ArgfsTer21) is highlighted by the vertical purple bar. (B) Targeted-NGS sequence analysis identified a heterozygous variant c.735dup (p.Gly246ArgfsTer21) in PDX1, a duplication of adenosine at exon 2 in the proband. The c.735dup heterozygous mutation is indicated by the red arrow. The variant was absent in electropherograms from the mother. Confirmation of the NGS-detected variant by Sanger sequencing. NGS, next-generation sequencing.

Fig. 3.

Changes in glycated hemoglobin (HbA1c) level in the proband over a four-year follow-up period.

Table 1.

Clinical characteristics of the family members with diabetes.

Characteristic	Proband	Mother
PDX1 variant	Present	Absent
Sex	Female	Female
BMI (kg/m²)	17.54	21.8
Current age (yr)	14	43
Age at diagnosis of diabetes (yr)	10	26
Current diabetes treatment	Insulin degludec + metformin	Gliclazide + metformin
Comorbidities	None	None
Range of HbA1c
NGSP (%)	6.1–13.6	7.1–12.9
IFCC (mmol/mol)	43.1–125.0	54.1–117.7
HbA1c
At diagnosis of diabetes (%)	13.6	12.9
At recent follow-up (%)	6.3	6.1
Range of fasting insulin (microU/mL)	2.21–7.04	NA
Range of fasting C-peptide (ng/mL)	0.48–1.08	0.51–0.78
Fasting C-peptide
At diagnosis of diabetes (ng/mL)	0.84	0.51
At recent follow-up (ng/mL)	0.48	NA
Postprandial C-peptide
At diagnosis of diabetes (ng/mL)	24.44	NA
At recent follow-up (ng/mL)	NA	NA
Range of fasting glucose (mg/dL)	80–505	81–278
Microalbuminuria	Negative	Positive
Fundoscopic examination	Negative	Nonproliferative diabetic retinopathy
β-cell antibodies	Negative	NA

BMI, body mass index; HbA1c, glycated hemoglobin A1c; NGSP, National Glycohemoglobin Standardization Program; IFCC, International Federation of Clinical Chemistry; NA, not available.

Table 2.

Clinical features, treatment, and mutation of PDX1 gene of patients diagnosed with maturity-onset diabetes of the young type 4 in previous studies.

Study	Sex (M/F)/current age (yr)	Age at diagnosis of diabetes (yr)	HbA1c at genetic testing (%)	Clinical features	Treatment	Genetic mutation/protein mutation
Stoffers et al., [6] 1997	F/5	0	NA	Family history: 5 generations	Diet, oral antidiabetic medication	c.188delC/p. Pro63fsTer2
Fajans et al., [11] 2010	M/1	0	NA	Family history: 5 generations	Insulin	c.188delC/p. Pro63fsTer2
Anık et al., [20] 2015	F/NA	14	NA	BMI (kg/m²): 23	Insulin	c.164G>A/p. Gly55Asp
				Specific symptom: hyperglycemia related to corticosteroid
				Accompanying pathology: Dress syndrome
Mang rum et al., [15] 2015	M/26	26	9.3	BMI (kg/m²): 23, C-peptide (ng/mL): 1.6	Metformin + pioglitazone	c .6 94_697 del8GGCGinsAGCT/p.Gly232SerfsTer2
				Family history: 3 generations	→Glyburide 5mg + pioglitazone
				Islet autoantibodies: negative	→Glyburide 5mg + pioglitazone
				Episode of DKA: none	→DDP-4 inhibitor + pioglitazone
				Renal function: normal
				β-cell antibodies: negative
Caetano et al., [12] 2018	M/52	14	7.4	BMI (kg/m²): 21.8, C-peptide (nmol/L): 0.47	Gliclazide +NPH insulin	c.188delC/p.Pro63Argfs*60
				Family history: 3 generations, Islet autoantibodies: negative
				Episode of DKA: none, renal function: normal
				β-cell antibodies: negative
Deng et al., [16] 2019	M/14	14	10.7	BMI (kg/m²): 24.4, Fasting C-peptide (ng/mL): 1.10	Metformin 0.5g QD →None	c.463C>A/p.Arg155Ser
Deng et al., [16] 2019	M/14	14	10.7	Family history: 2 generations, β-cell antibodies: negative	Metformin 0.5g QD →None	c.463C>A/p.Arg155Ser
Abreu et al., [17] 2021	F/46	27	9.9	BMI (kg/m²): 23.9	NPH + regular fast-acting insulin	c.532G >A/ p.Glu178Lys
				Family history: 3 generations, β-cell antibodies: negative
				Accompanying pathology: gestational diabetic mellitus
Al-Kandari et al., [18] 2021	M/18	16	9.3	BMI (kg/m²): 25.7, Family history: 3 generations	Insulin	c.461C > G/p.Thr154Arg
The present case	F/14	10	9.0	BMI (kg/m²): 17.54, Fasting C-peptide (ng/mL): 0.84	Insulin+ metformin	c.735dup/p.Gly246ArgfsTer21
				Family history: 2 generations
				β-cell antibodies: negative

BMI, body mass index; DPP-4 inhibitor, dipeptidyl peptidase 4 inhibitor; DKA, diabetic ketoacidosis; HbA1c, glycated hemoglobin A1c; NA, not available; NPH, neutral protamine hagedo.

References

1. Mayer-Davis EJ, Lawrence JM, Dabelea D, Divers J, Isom S, Dolan L, et al. Incidence trends of type 1 and type 2 diabetes among youths, 2002-2012. N Engl J Med 2017;376:1419–29.

2. Hattersley AT, Greeley SAW, Polak M, Rubio-Cabezas O, Njølstad PR, Mlynarski W, et al. ISPAD clinical practice consensus guidelines 2018: the diagnosis and management of monogenic diabetes in children and adolescents. Pediatr Diabetes 2018;19 Suppl 27:47–63.

3. Yeung RO, Hannah-Shmouni F, Niederhoffer K, Walker MA. Not quite type 1 or type 2, what now? Review of monogenic, mitochondrial, and syndromic diabetes. Rev Endocr Metab Disord 2018;19:35–52.

4. Nkonge KM, Nkonge DK, Nkonge TN. The epidemiology, molecular pathogenesis, diagnosis, and treatment of maturity-onset diabetes of the young (MODY). Clin Diabetes Endocrinol 2020;6:20.

5. Xie F, Chan JC, Ma RC. Precision medicine in diabetes prevention, classification and management. J Diabetes Investig 2018;9:998–1015.

6. Stoffers DA, Ferrer J, Clarke WL, Habener JF. Early-onset type-II diabetes mellitus (MODY4) linked to IPF1. Nat Genet 1997;17:138–9.

7. Yang YS, Kwak SH, Park KS. Update on monogenic diabetes in Korea. Diabetes Metab J 2020;44:627–39.

8. Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med 2015;17:405–24.

9. Heuvel-Borsboom H, de Valk HW, Losekoot M, Westerink J. Maturity onset diabetes of the young: seek and you will find. Neth J Med 2016;74:193–200.

10. Shields BM, Hicks S, Shepherd MH, Colclough K, Hattersley AT, Ellard S. Maturity-onset diabetes of the young (MODY): how many cases are we missing? Diabetologia 2010;53:2504–8.

11. Fajans SS, Bell GI, Paz VP, Below JE, Cox NJ, Martin C, et al. Obesity and hyperinsulinemia in a family with pancreatic agenesis and MODY caused by the IPF1 mutation Pro63fsX60. Transl Res 2010;156:7–14.

12. Caetano LA, Santana LS, Costa-Riquetto AD, Lerario AM, Nery M, Nogueira GF, et al. PDX1 -MODY and dorsal pancreatic agenesis: new phenotype of a rare disease. Clin Genet 2018;93:382–6.

13. Stanik J, Dusatkova P, Cinek O, Valentinova L, Huckova M, Skopkova M, et al. de novo mutations of GCK, HNF1A and HNF4A may be more frequent in MODY than previously assumed. Diabetologia 2014;57:480–4.

14. Delvecchio M, Pastore C, Giordano P. Treatment options for MODY patients: a systematic review of literature. Diabetes Ther 2020;11:1667–85.

15. Mangrum C, Rush E, Shivaswamy V. Genetically targeted dipeptidyl peptidase-4 inhibitor use in a patient with a novel mutation of MODY type 4. Clin Med Insights Endocrinol Diabetes 2015;8:83–6.

16. Deng M, Xiao X, Zhou L, Wang T. First Case Report of maturity-onset diabetes of the young type 4 pedigree in a chinese family. Front Endocrinol (Lausanne) 2019;10:406.

17. Abreu GM Miss, Tarantino RM, da Fonseca ACP, de Souza RB, Soares CAPD, Cabello PH, et al. PDX1-MODY: a rare missense mutation as a cause of monogenic diabetes. Eur J Med Genet 2021;64:104194.

18. Al-Kandari H, Al-Abdulrazzaq D, Davidsson L, Nizam R, Jacob S, Melhem M, et al. Identification of Maturity-Onset-Diabetes of the Young (MODY) mutations in a country where diabetes is endemic. Sci Rep 2021;11:16060.

19. Özdemir TR, Kırbıyık Ö, Dündar BN, Abacı A, Kaya ÖÖ, Çatlı G, et al. Targeted next generation sequencing in patients with maturity-onset diabetes of the young (MODY). J Pediatr Endocrinol Metab 2018;31:1295–304.

20. Anık A, Çatlı G, Abacı A, Sarı E, Yeşilkaya E, Korkmaz HA, et al. Molecular diagnosis of maturity-onset diabetes of the young (MODY) in Turkish children by using targeted next-generation sequencing. J Pediatr Endocrinol Metab 2015;28:1265–71.